Richard D Baird

22PUBLICATIONS
192CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Oct 13, 2026
Using Joint Models in Phase I Dose-Finding Designs in Oncology: Considerations for Frequentist Approaches.

|Feb 03, 2026
PI3K Inhibition in Combination with Tamoxifen in Patients with Metastatic HR+/HER2- Breast Cancer: Clinical and Circulating Tumor DNA Results.

Rosie A B Voorthuis, Mafalda Oliveira, Annelot G J van Rossum

|Jan 06, 2026
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial.

Rebecca A Burrell, Sanjeev Kumar, Elena Provenzano

|Oct 29, 2025
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial.

Iseult M Browne, Javier Pascual, Rosalind J Cutts

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Jul 01, 2025
Using circulating tumor DNA as a novel biomarker of efficacy for dose-finding designs in oncology.

Xijin Chen, Pavel Mozgunov, Richard D Baird

Pageof 4

Frequent Collaborators

6 joint publications

Iain R Macpherson

5 joint publications

Carlos Caldas

4 joint publications

Lucy S Kilburn

4 joint publications

Alistair Ring